In breast cancer cases, ERO1L also proved to be able to promote angiogenesis by augmentation of VEGF production [7], support tumoral immune escape through PD-1 [15], and serve as a novel predictor for poor prognosis of breast cancer [14]. Here, ERO1A is linked to breast carcinoma.